NCT06274268 Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments
| NCT ID | NCT06274268 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Metropole Savoie |
| Condition | Sarcopenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 700 participants |
| Start Date | 2024-06-24 |
| Primary Completion | 2027-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 700 participants in total. It began in 2024-06-24 with a primary completion date of 2027-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn about the effect of sarcopenic status on the occurrence of treatment-related toxicity during the first course of anti-cancer treatment in several types of cancers. The main question it aims to answer is : Is sarcopenia a predictive marker for the occurrence of toxicity in the initial phase of cancer treatment? The evaluation will focus on the body composition of the participants, assessed by impedancemetry, and on their muscular performance by standardized physical tests.
Eligibility Criteria
Inclusion Criteria: * Patients over 18 years old * Patient with a diagnosis of a histologically proven solid malignant tumor with an indication for systemic treatment during initial treatment. * CT/PET performed within 45 days before initiation of systemic treatment. * Patient able to sign informed consent for participation in the study * Patient affiliated to a social security system Exclusion Criteria: * History of cancer in the five years preceding inclusion other than localized skin or cervical cancers. * Patient with cancer not requiring systemic treatment. * Pregnant women. * Patient with a pace maker or defibrillator * Patient deprived of liberty or benefiting from a legal protection measure
Contact & Investigator
Aurelie FILLON
PRINCIPAL INVESTIGATOR
Centre Hospitalier Metropole Savoie
Frequently Asked Questions
Who can join the NCT06274268 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sarcopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06274268 currently recruiting?
Yes, NCT06274268 is actively recruiting participants. Contact the research team at aurelie.fillon@ch-metropole-savoie.fr for enrollment information.
Where is the NCT06274268 trial being conducted?
This trial is being conducted at Chambéry, France.
Who is sponsoring the NCT06274268 clinical trial?
NCT06274268 is sponsored by Centre Hospitalier Metropole Savoie. The principal investigator is Aurelie FILLON at Centre Hospitalier Metropole Savoie. The trial plans to enroll 700 participants.